Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway

Studies have confirmed that olanzapine, the mainstay treatment for schizophrenia, triggers metabolic diseases, including non-alcoholic fatty liver disease (NAFLD). However, the etiology of olanzapine-induced NAFLD is poorly understood. Proprotein convertase subtilisin kexin type 9 (PCSK9) is involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wenqiang, Ding, Chen, Huang, Piaopiao, Ran, Juanli, Lian, Pingan, Tang, Yaxin, Dai, Wen, Huang, Xiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979948/
https://www.ncbi.nlm.nih.gov/pubmed/35379885
http://dx.doi.org/10.1038/s41598-022-09610-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979948/
https://www.ncbi.nlm.nih.gov/pubmed/35379885
http://dx.doi.org/10.1038/s41598-022-09610-1

Ejemplares similares